Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial
Reuters2026/09/09 06:46- Elicera Therapeutics will advance ELC-301 into Phase IIa in its CARMA study in B-cell lymphoma, using the highest tested dose.
- The trial’s safety panel backed the dose selection with no major safety issues reported in the completed Phase I portion.
- Earlier interim results were already presented, showing broad disease control with many patients achieving tumor shrinkage, including some reaching disease-free status.
- The company plans to present preliminary Phase I efficacy results for all 12 patients once the last patient completes a one-month assessment.
- Phase IIa dosing is expected to start once Sweden’s Medical Products Agency clears the protocol to proceed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sasol agrees to sell Nitrates business to Enaex Africa, keeps 23% stake
The United States implements import bans on some Canadian products. Which US stocks are affected?
The United States has imposed tariffs on certain Canadian products, making these U.S. stocks worth watching.
Jing Rui Wang Pu (JRWP.US) makes another attempt to list on Nasdaq, raising the fundraising amount significantly to $31 million.
JRWP.US resubmitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) on Tuesday.
Asiamet Resources LTIP Tranche 1 vests, converts 79.85 million performance rights into shares
Crypto prices
More
